DEA will submit formal written opposition to any NDAA provision creating ibogaine veteran access that bypasses Schedule I review, before December 31 2026.

Some in Congress want to create a fast track for military veterans to access ibogaine without waiting for Schedule I review (the formal drug classification process). The DEA has legal standing and institutional reasons to block this—they will write an official letter or Congressional statement opposing any law that lets ibogaine bypass the normal review process.

DEA has institutional incentive and procedural standing to oppose Schedule I bypass via NDAA. The DOJ GC opinion request sub-claim is speculative and unfalsifiable without a document trail; it is removed. Resolved by existence of a public DEA letter, Congressional Record statement, or documented DOJ referral.